March 31, 2025
Explore the AVO regimen for high-risk CLL patients, including the role of BTK inhibitors and time-limited therapies. Gain insights into tailored treatment strategies.
Chemotherapy related articles.
October 31, 2024
The advancements in neoadjuvant immunotherapy for Merkel cell carcinoma represent a significant step forward in the treatment of this aggressive skin cancer.
July 20, 2024
Discover innovative therapeutic strategies targeting quiescent cancer cells to combat tumor resistance and prevent relapse. Learn how to overcome treatment challenges.
April 22, 2024
Introduction to NINLARO® (ixazomib) in combination with lenalidomide NINLARO® (ixazomib) in combination with lenalidomide is a treatment strategy used for multiple myeloma, a type of cancer […]
April 20, 2024
Understanding Diffuse Lower-Grade Glioma is crucial for providing effective strategies to enhance the quality of life for patients.
Diffuse lower-grade gliomas are brain tumors that have distinct characteristics and challenges.
April 12, 2024
Mercaptopurine, often referred to by its chemical name 6-mercaptopurine or simply 6-MP, stands as a pivotal medication in the oncology sphere, particularly within the context of treating childhood Acute Lymphoblastic Leukemia (ALL).
February 26, 2024
Mannitol is used after cisplatin treatment to prevent or reduce the risk of cisplatin-induced nephrotoxicity, which is a major concern associated with cisplatin chemotherapy. Cisplatin is a widely used chemotherapeutic drug for various types of cancer, but its use is often limited by its potential to cause kidney damage.
February 24, 2024
Heparin, available as both unfractionated and low-molecular-weight forms, has been extensively studied for its potential benefits in cancer patients. Low molecular weight heparin's role in both preventing and treating venous thromboembolism in patients, a common complication in cancer patients, has been the subject of systematic review and numerous randomized clinical trials. Furthermore, heparin has shown promising effects in managing VTE in patients undergoing cancer therapy, including those with advanced pancreatic cancer.
February 13, 2024
Palbociclib (Ibrance) is a CDK4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC).
